Literature DB >> 12206802

Multivariate evaluation of the functional recovery obtained by the overexpression of utrophin in skeletal muscles of the mdx mouse.

Jean-Marie Gillis1.   

Abstract

This paper summarizes the various aspects of functional recovery obtained in dystrophin-deficient muscles of the mdx mice where utrophin was overexpressed. This includes preliminary results on tetracycline-controlled expression of utrophin. It is shown that overexpression of utrophin leads to major functional improvements and that full-length utrophin is more efficient than truncated utrophin, missing a part of the central rod-segment. A generalized way of presenting improvements obtained by any treatment in the form of a 'recovery score' is emphasized. The quantitative aspect of the replacement of dystrophin by utrophin is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206802     DOI: 10.1016/s0960-8966(02)00088-3

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Authors:  Ava Yun Lin; Ewa Prochniewicz; Davin M Henderson; Bin Li; James M Ervasti; David D Thomas
Journal:  J Mol Biol       Date:  2012-04-11       Impact factor: 5.469

2.  Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice.

Authors:  Raffaella Willmann; Annamaria De Luca; Michael Benatar; Miranda Grounds; Judith Dubach; Jean-Marc Raymackers; Kanneboyina Nagaraju
Journal:  Neuromuscul Disord       Date:  2011-07-06       Impact factor: 4.296

3.  A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy.

Authors:  Elizabeth M Gibbs; Rachelle H Crosbie-Watson
Journal:  J Vis Exp       Date:  2017-12-29       Impact factor: 1.355

4.  CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres.

Authors:  Margaret Durko; Carol Allen; Josephine Nalbantoglu; George Karpati
Journal:  J Muscle Res Cell Motil       Date:  2010-08-13       Impact factor: 2.698

5.  Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse.

Authors:  C George Carlson; Kay Bruemmer; Jenna Sesti; Casey Stefanski; Heather Curtis; Jeffrey Ucran; Jennifer Lachey; Jasbir S Seehra
Journal:  Muscle Nerve       Date:  2011-04-01       Impact factor: 3.217

Review 6.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

7.  Loss of sarcospan exacerbates pathology in mdx mice, but does not affect utrophin amelioration of disease.

Authors:  Elizabeth M Gibbs; Jackie L McCourt; Kara M Shin; Katherine G Hammond; Jamie L Marshall; Rachelle H Crosbie
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

8.  Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea.

Authors:  Yoshiko Nakae; Olivier M Dorchies; Peter J Stoward; Benno F Zimmermann; Christina Ritter; Urs T Ruegg
Journal:  Histochem Cell Biol       Date:  2012-02-14       Impact factor: 4.304

9.  Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.

Authors:  Daniel Cabrera; Jaime Gutiérrez; Claudio Cabello-Verrugio; Maria Gabriela Morales; Sergio Mezzano; Ricardo Fadic; Juan Carlos Casar; Juan L Hancke; Enrique Brandan
Journal:  Skelet Muscle       Date:  2014-03-21       Impact factor: 4.912

10.  Improving translational studies: lessons from rare neuromuscular diseases.

Authors:  Dominic Wells
Journal:  Dis Model Mech       Date:  2015-10-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.